P. Massari

A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

Flavio Vincenti, B Charpentier, Yves Vanrenterghem et al. · American Journal of Transplantation · 2010 · 931 citations

Transplant Rejection, Urology, Transplantation +13

Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients

Flavio Vincenti, Christian P. Larsen, Josefina Alberú et al. · American Journal of Transplantation · 2011 · 308 citations · Full text

Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

José Osmar Medina Pestana, J.M. Grinyó, Yves Vanrenterghem et al. · American Journal of Transplantation · 2012 · 259 citations · Full text

Switching from Calcineurin Inhibitor-based Regimens to a Belatacept-based Regimen in Renal Transplant Recipients

Lionel Rostaing, P. Massari, Valter Duro Garcı́a et al. · Clinical Journal of the American Society of Nephrology · 2010 · 183 citations · Full text

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study

Stefan P. Berger, Claudia Sommerer, Oliver Witzke et al. · American Journal of Transplantation · 2019 · 145 citations · Full text